- Conditions
- Thyroid Gland Nodule
- Interventions
- Diagnostic DNA Methylation Signature
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 448
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Thyroid Gland Carcinoma
- Interventions
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer, Bronchial Carcinoid, Gastroenteropancreatic Neuroendocrine Neoplasm
- Interventions
- 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Papillary Thyroid Cancer
- Interventions
- Radiofrequency Ablation
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy, Pituitary Disease, Thyroid Disease
- Interventions
- TRH (Thyrotropin Releasing Hormone)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
- Procedure · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Interventions
- Counseling, Interview, Questionnaire Administration
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Parathyroid Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Larynx, Stage IIIB Non-small Cell Lung Cancer, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Follicular Thyroid Cancer, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Papillary Thyroid Cancer, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Follicular Thyroid Cancer, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Papillary Thyroid Cancer, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Follicular Thyroid Cancer, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Papillary Thyroid Cancer, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Thryoid Gland Nonmedullary Carcinoma, Thyroid Gland Medullary Carcinoma, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- gefitinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
- Interventions
- Selpercatinib, Sodium Iodine I-131, rhTSH
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more
- Conditions
- Thyroid Carcinoma, Anaplastic
- Interventions
- Lenvatinib 24 mg
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Breast Cancer, Fatigue, Hypothyroidism
- Interventions
- physiologic testing, fatigue assessment and management, management of therapy complications
- Other · Procedure
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 20 Years to 80 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
- Conditions
- Neoplasms
- Interventions
- Vemurafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 9
- States / cities
- Torrance, California • New Haven, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
- Interventions
- XL281, famotidine
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more
- Conditions
- Breast Cancer
- Interventions
- Seaweed and Soy Protein, Placebo and Soy Protein
- Dietary Supplement
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 1999
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
- Interventions
- sorafenib
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Procedure · Other · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- Trametinib, Paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
- Interventions
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
- Procedure · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Thyroid Cancer
- Interventions
- XL184, Placebo
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
- Interventions
- SNP analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Saad A Khan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cancer
- Interventions
- isolated perfusion, melphalan
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Papillary Carcinoma, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Poorly Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Oncocytic Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Follicular Carcinoma AJCC v8, Stage III Thyroid Gland Papillary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Follicular Carcinoma AJCC v8, Stage IV Thyroid Gland Papillary Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging, Zanzalintinib
- Procedure · Other · Drug
- Lead sponsor
- Jochen Lorch
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Torrance, California • Chicago, Illinois
- Conditions
- Thyroid Nodule
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania